Article
Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.
The Journal of infectious diseases - 4 Sept 2022
Chou Sunwen, Song Kening, Wu Jingyang, Bo Tien, Crumpacker Clyde
Abstract excerpt
BACKGROUND: In separate phase 2 trials, 120 patients received maribavir for cytomegalovirus (CMV) infection failing conventional therapy (trial 202) and 119 received maribavir for asymptomatic infection (trial 203). Overall, 172 cleared their CMV infection (CMV DNA <200 copies/mL) within 6 weeks. METHODS: Baseline and posttreatment plasma samples were tested for mutations in viral genes UL97, UL54, and/or UL27....
Topics
- Humans
- Cytomegalovirus
- Drug Resistance, Viral
- Antiviral Agents
- Phosphotransferases (Alcohol Group Acceptor)
- Cytomegalovirus Infections
- Ganciclovir
- Mutation
- Phenotype